Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Verena Becker is active.

Publication


Featured researches published by Verena Becker.


Science | 2010

Covering a Broad Dynamic Range: Information Processing at the Erythropoietin Receptor

Verena Becker; Marcel Schilling; Julie Bachmann; Ute Baumann; Andreas Raue; Thomas Maiwald; Jens Timmer; Ursula Klingmüller

Seeing EPO The supply of red blood cells in mammals is controlled by the cytokine erythropoietin (EPO). In physiological situations, the concentration of EPO can change by 1000-fold. Becker et al. (p. 1404, published online 20 May) used a combination of mathematical modeling and experimental analysis to discern how cells can maintain a linear response to such a broad range of EPO concentrations. Critical features included internalization of EPO-bound receptors and subsequent degradation of the EPO ligand. Replenishment of receptors at the cell surface required a large supply of EPO receptors maintained in reserve inside the cell. These mechanisms allow cells to experience large increases in EPO concentration without becoming refractory to further stimulation. Modeling and experiments help to explain responsiveness of red blood cell precursors to very large changes in a proliferative signal. Cell surface receptors convert extracellular cues into receptor activation, thereby triggering intracellular signaling networks and controlling cellular decisions. A major unresolved issue is the identification of receptor properties that critically determine processing of ligand-encoded information. We show by mathematical modeling of quantitative data and experimental validation that rapid ligand depletion and replenishment of the cell surface receptor are characteristic features of the erythropoietin (Epo) receptor (EpoR). The amount of Epo-EpoR complexes and EpoR activation integrated over time corresponds linearly to ligand input; this process is carried out over a broad range of ligand concentrations. This relation depends solely on EpoR turnover independent of ligand binding, which suggests an essential role of large intracellular receptor pools. These receptor properties enable the system to cope with basal and acute demand in the hematopoietic system.


Blood | 2008

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2

Florian Grebien; Marc Kerenyi; Boris Kovacic; Thomas Kolbe; Verena Becker; Helmut Dolznig; Klaus Pfeffer; Ursula Klingmüller; Mathias Müller; Hartmut Beug; Ernst W. Müllner; Richard Moriggl

Erythropoiesis requires erythropoietin (Epo) and stem cell factor (SCF) signaling via their receptors EpoR and c-Kit. EpoR, like many other receptors involved in hematopoiesis, acts via the kinase Jak2. Deletion of EpoR or Janus kinase 2 (Jak2) causes embryonic lethality as a result of defective erythropoiesis. The contribution of distinct EpoR/Jak2-induced signaling pathways (mitogen-activated protein kinase, phosphatidylinositol 3-kinase, signal transducer and activator of transcription 5 [Stat5]) to functional erythropoiesis is incompletely understood. Here we demonstrate that expression of a constitutively activated Stat5a mutant (cS5) was sufficient to relieve the proliferation defect of Jak2(-/-) and EpoR(-/-) cells in an Epo-independent manner. In addition, tamoxifen-induced DNA binding of a Stat5a-estrogen receptor (ER)* fusion construct enabled erythropoiesis in the absence of Epo. Furthermore, c-Kit was able to enhance signaling through the Jak2-Stat5 axis, particularly in lymphoid and myeloid progenitors. Although abundance of hematopoietic stem cells was 2.5-fold reduced in Jak2(-/-) fetal livers, transplantation of Jak2(-/-)-cS5 fetal liver cells into irradiated mice gave rise to mature erythroid and myeloid cells of donor origin up to 6 months after transplantation. Cytokine- and c-Kit pathways do not function independently of each other in hematopoiesis but cooperate to attain full Jak2/Stat5 activation. In conclusion, activated Stat5 is a critical downstream effector of Jak2 in erythropoiesis/myelopoiesis, and Jak2 functionally links cytokine- with c-Kit-receptor tyrosine kinase signaling.


Chaos | 2010

Identifiability and observability analysis for experimental design in nonlinear dynamical models

Andreas Raue; Verena Becker; Ursula Klingmüller; Jens Timmer

Dynamical models of cellular processes promise to yield new insights into the underlying systems and their biological interpretation. The processes are usually nonlinear, high dimensional, and time-resolved experimental data of the processes are sparse. Therefore, parameter estimation faces the challenges of structural and practical nonidentifiability. Nonidentifiability of parameters induces nonobservability of trajectories, reducing the predictive power of the model. We will discuss a generic approach for nonlinear models that allows for identifiability and observability analysis by means of a realistic example from systems biology. The results will be utilized to design new experiments that enhance model predictiveness, illustrating the iterative cycle between modeling and experimentation in systems biology.


BMC Systems Biology | 2008

A systems biology approach to analyse amplification in the JAK2-STAT5 signalling pathway

Julio Vera; Julie Bachmann; Andrea C. Pfeifer; Verena Becker; José A. Hormiga; Néstor V. Torres Darias; Jens Timmer; Ursula Klingmüller; Olaf Wolkenhauer

BackgroundThe amplification of signals, defined as an increase in the intensity of a signal through networks of intracellular reactions, is considered one of the essential properties in many cell signalling pathways. Despite of the apparent importance of signal amplification, there have been few attempts to formalise this concept.ResultsIn this work we investigate the amplification and responsiveness of the JAK2-STAT5 pathway using a kinetic model. The recruitment of EpoR to the plasma membrane, activation by Epo, and deactivation of the EpoR/JAK2 complex are considered as well as the activation and nucleocytoplasmic shuttling of STAT5. Using qualitative biological knowledge, we first establish the structure of a general power-law model. We then generate a family of models from which we select suitable candidates. The parameter values of the model are estimated from experimental quantitative time-course data. The final model, whether it is conventional model with fixed predefined integer kinetic orders or a model with variable non-integer kinetic orders, is selected on the basis of a good agreement between simulations and the experimental data. The model is used to analyse the responsiveness and amplification properties of the pathway with sustained, transient, and oscillatory stimulation.ConclusionThe selected kinetic model predicts that the system acts as an amplifier with maximum amplification and sensitivity for input signals whose intensity match physiological values for Epo concentration and with duration in the range of one to 100 minutes. The response of the system reaches saturation for more intense and longer stimulation with Epo. We hypothesise that these properties of the system directly relate to the saturation of Epo receptor activation, its low recruitment to the plasma membrane and intense deactivation as predicted by the model.


Journal of Internal Medicine | 2012

Predictive mathematical models of cancer signalling pathways.

Julie Bachmann; Andreas Raue; Marcel Schilling; Verena Becker; Jens Timmer; Ursula Klingmüller

Abstract.  Bachmann J, Raue A, Schilling M, Becker V, Timmer J, Klingmüller U (German Cancer Research Center, Heidelberg; BIOSS Centre for Biological Signalling Studies, Freiburg; and University of Freiburg, Freiburg; Germany). Predictive mathematical models of cancer signalling pathways (Key Symposium). J Intern Med 2012; 271:155–165.


Molecular Systems Biology | 2017

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

Mohammad Fallahi-Sichani; Verena Becker; Benjamin Izar; Gregory J. Baker; Jia-Ren Lin; Sarah A. Boswell; Parin Shah; Asaf Rotem; Levi A. Garraway; Peter K. Sorger

Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of the promise of precision cancer therapy but also highlights problems with drug resistance that limit patient benefit. We use live‐cell imaging, single‐cell analysis, and molecular profiling to show that exposure of tumor cells to RAF/MEK inhibitors elicits a heterogeneous response in which some cells die, some arrest, and the remainder adapt to drug. Drug‐adapted cells up‐regulate markers of the neural crest (e.g., NGFR), a melanocyte precursor, and grow slowly. This phenotype is transiently stable, reverting to the drug‐naïve state within 9 days of drug withdrawal. Transcriptional profiling of cell lines and human tumors implicates a c‐Jun/ECM/FAK/Src cascade in de‐differentiation in about one‐third of cell lines studied; drug‐induced changes in c‐Jun and NGFR levels are also observed in xenograft and human tumors. Drugs targeting the c‐Jun/ECM/FAK/Src cascade as well as BET bromodomain inhibitors increase the maximum effect (Emax) of RAF/MEK kinase inhibitors by promoting cell killing. Thus, analysis of reversible drug resistance at a single‐cell level identifies signaling pathways and inhibitory drugs missed by assays that focus on cell populations.


Biochemistry | 2008

Packing Density of the Erythropoietin Receptor Transmembrane Domain Correlates with Amplification of Biological Responses

Verena Becker; Durba Sengupta; Robin Ketteler; G. Matthias Ullmann; Jeremy C. Smith; Ursula Klingmüller

The formation of signal-promoting dimeric or oligomeric receptor complexes at the cell surface is modulated by self-interaction of their transmembrane (TM) domains. To address the importance of TM domain packing density for receptor functionality, we examined a set of asparagine mutants in the TM domain of the erythropoietin receptor (EpoR). We identified EpoR-T242N as a receptor variant that is present at the cell surface similar to wild-type EpoR but lacks visible localization in vesicle-like structures and is impaired in efficient activation of specific signaling cascades. Analysis by a molecular modeling approach indicated an increased interhelical distance for the EpoR-T242N TM dimer. By employing the model, we designed additional mutants with increased or decreased packing volume and confirmed a correlation between packing volume and biological responsiveness. These results propose that the packing density of the TM domain provides a novel layer for fine-tuned regulation of signal transduction and cellular decisions.


PLOS ONE | 2011

Prognostic significance of Erythropoietin in pancreatic adenocarcinoma

Thilo Welsch; Stefanie Zschäbitz; Verena Becker; Thomas Giese; Frank Bergmann; Ulf Hinz; Shereen Keleg; Anette Heller; Bence Sipos; Ursula Klingmüller; Markus W. Büchler; Jens Werner; Nathalia A. Giese

Background Erythropoietin (Epo) administration has been reported to have tumor-promoting effects in anemic cancer patients. We investigated the prognostic impact of endogenous Epo in patients with pancreatic ductal adenocarcinoma (PDAC). Methodology The clinico-pathological relevance of hemoglobin (Hb, n = 150), serum Epo (sEpo, n = 87) and tissue expression of Epo/Epo receptor (EpoR, n = 104) was analyzed in patients with PDAC. Epo/EpoR expression, signaling, growth, invasion and chemoresistance were studied in Epo-exposed PDAC cell lines. Results Compared to donors, median preoperative Hb levels were reduced by 15% in both chronic pancreatitis (CP, p<0.05) and PDAC (p<0.001), reaching anemic grade in one third of patients. While inversely correlating to Hb (r = −0.46), 95% of sEPO values lay within the normal range. The individual levels of compensation were adequate in CP (observed to predicted ratio, O/P = 0.99) but not in PDAC (O/P = 0.85). Strikingly, lower sEPO values yielding inadequate Epo responses were prominent in non-metastatic M0-patients, whereas these parameters were restored in metastatic M1-group (8 vs. 13 mU/mL; O/P = 0.82 vs. 0.96; p<0.01)—although Hb levels and the prevalence of anemia were comparable. Higher sEpo values (upper quartile ≥16 mU/ml) were not significantly different in M0 (20%) and M1 (30%) groups, but were an independent prognostic factor for shorter survival (HR 2.20, 10 vs. 17 months, p<0.05). The pattern of Epo expression in pancreas and liver suggested ectopic release of Epo by capillaries/vasa vasorum and hepatocytes, regulated by but not emanating from tumor cells. Epo could initiate PI3K/Akt signaling via EpoR in PDAC cells but failed to alter their functions, probably due to co-expression of the soluble EpoR isoform, known to antagonize Epo. Conclusion/Significance Higher sEPO levels counteract anemia but worsen outcome in PDAC patients. Further trials are required to clarify how overcoming a sEPO threshold ≥16 mU/ml by endogenous or exogenous means may predispose to or promote metastatic progression.


BMC Systems Biology | 2012

In silico labeling reveals the time-dependent label half-life and transit-time in dynamical systems.

Thomas Maiwald; Julie Blumberg; Andreas Raue; Stefan Hengl; Marcel Schilling; Sherwin K. B. Sy; Verena Becker; Ursula Klingmüller; Jens Timmer

BackgroundMathematical models of dynamical systems facilitate the computation of characteristic properties that are not accessible experimentally. In cell biology, two main properties of interest are (1) the time-period a protein is accessible to other molecules in a certain state - its half-life - and (2) the time it spends when passing through a subsystem - its transit-time. We discuss two approaches to quantify the half-life, present the novel method of in silico labeling, and introduce the label half-life and label transit-time. The developed method has been motivated by laboratory tracer experiments. To investigate the kinetic properties and behavior of a substance of interest, we computationally label this species in order to track it throughout its life cycle. The corresponding mathematical model is extended by an additional set of reactions for the labeled species, avoiding any double-counting within closed circuits, correcting for the influences of upstream fluxes, and taking into account combinatorial multiplicity for complexes or reactions with several reactants or products. A profile likelihood approach is used to estimate confidence intervals on the label half-life and transit-time.ResultsApplication to the JAK-STAT signaling pathway in Epo-stimulated BaF3-EpoR cells enabled the calculation of the time-dependent label half-life and transit-time of STAT species. The results were robust against parameter uncertainties.ConclusionsOur approach renders possible the estimation of species and label half-lives and transit-times. It is applicable to large non-linear systems and an implementation is provided within the PottersWheel modeling framework (http://www.potterswheel.de).


Advances in Experimental Medicine and Biology | 2012

Receptor dynamics in signaling.

Verena Becker; Jens Timmer; Ursula Klingmüller

Reliable inter- and intracellular communication is central to both the development and the integrity of multicellular organisms. Key mediators of these processes are cell surface receptors that perceive and convert extracellular cues to trigger intracellular signaling networks and ultimately a phenotypic response. Deregulation of signal transduction leads to a variety of diseases, and aberrations in receptor proteins are very common in various cancer types. Therefore, cell surface receptors have been established as major targets in drug discovery. However, in order to efficiently apply therapeutics, it is crucial to gain knowledge about design principles of receptor signaling. In this chapter, we will discuss signal transduction at the receptor level for examples from different receptor classes.

Collaboration


Dive into the Verena Becker's collaboration.

Top Co-Authors

Avatar

Ursula Klingmüller

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Jens Timmer

University of Freiburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marcel Schilling

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge